TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05574504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: avelumab (PD-L1 inhibitor immunotherapy) + lurbinectedin
Description: Avelumab 800 mg IV q 2 weeks (days 1,15, and 29 every 6 week cycle ) (premedication includes a H1 blocker, H2 blocker and Tylenol) Lurbinectedin 3.2 mg/m2 administered as a 1-h intravenous infusion once every 3 weeks (day 1 and 22 every 6 week cycle )~1 cycle= 6 weeks~Premedication for lurbinectedin:~* Corticosteroids (dexamethasone 8 mg intravenously or equivalent)~* Serotonin antagonists (ondansetron 8 mg intravenously or equivalent) Granulocyte-colony stimulating factor (G-CSF) or equivalent per ASCO guidelines per investigator discretion
Study: NCT05966701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSGJ-613
Description: SSGJ-613 subcutaneous injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo subcutaneous injection.
Study: NCT04298216

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasound Analysis of Inferior Vena Cavae (IVC)
Description: Novel Operators will attempt to visualize the Inferior Vena Cavae through two different views on the patient's body. The images taken will be interpreted by an expert ultrasound user to determine if the novel operator was successful in locating and evaluating the IVC.
Study: NCT05643105

Intervention type: PROCEDURE
Intervention: Any kind of colectomy
Description: This is a registry of surgical patients with colon cancer that are managed following current clinical practice in each participating center. The aim of this research is studying anastomotic leak rates and posible risk factors.
Study: NCT06065280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 MG
Description: Each group will be divided into 2 subgroups one on Empagliflozin and the other one on Dapagliflozin 10 MG daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 MG
Description: Each group will be divided into 2 subgroups one on Empagliflozin and the other one on Dapagliflozin 10 MG daily.
Study: NCT05375136

Intervention type: OTHER
Intervention: Non-interventional
Description: No intervention will be administered.
Study: NCT06065280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 MG
Description: Each group will be divided into 2 subgroups one on Empagliflozin and the other one on Dapagliflozin 10 MG daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 MG
Description: Each group will be divided into 2 subgroups one on Empagliflozin and the other one on Dapagliflozin 10 MG daily.
Study: NCT06095180

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: corticosteroid injection
Description: In the steroid group, 4 mL lidocaine 2% + 1 mL betamethasone injection will be administered under ultrasound guidance and conventional treatment will be given (conventional treatment includes piriformis stretching exercises. It will be stated that patients should do 2 sets a day and each set should be 10 repetition)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: dry needling
Description: In the dry needling group, a total of 3 sessions of dry needling will be performed once a week using a 0.60×100 mm sterile needle under ultrasound guidance and conventional treatment will be given ((conventional treatment includes piriformis stretching exercises. It will be stated that patients should do 2 sets a day and each set should be 10 repetition)

Intervention type: OTHER
Group type: OTHER
Intervention: exercise
Description: The conventional treatment group (control group) will be given piriformis stretching exercises including hip and knee flexion, hip abduction and external rotation in the supine position. It will be stated that patients should do 2 sets a day and each set should be 10 repetitions.
Study: NCT03966651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRRT with 177Lu-DOTATATE
Description: Children will receive 2 Peptide Receptor Radionuclide Therapy (PRRT) using 177Lu-DOTATATE administered intravenously at 6 weeks interval.
Study: NCT05175482

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Education
Description: health belief model based virtual education
Study: NCT04763135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Description: Orally disintegrating tablets of mirtazapine introduced at the dose of 15 mg and increased up to 45 mg per day during 56 days.~Doses escalation: based on symptom management and side effect assessment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: Orally disintegrating tablets of escitalopram introduced at the dose of 10 mg (or 5 mg for patients older than 65) and increased up to 20 mg per day during 56 days.~Doses escalation: based on symptom management and side effect assessment.
Study: NCT05334589

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prewarming
Description: When patients in the study group come to the Preoperative Care Unit (PCU), their body temperature will be measured. Patients in the study group will be placed in such a way that the 3M™ Bair Hugger™ Whole Body Blanket covers the patient's body and prewarmed with the 3M™ Bair Hugger™ Warming Unit for 30 minutes before anesthesia is given in the PCU. Heating unit temperature will be adjusted to 43°C in line with company recommendations. After the patients in the study group are warmed up for 30 minutes, the preheating process will be completed and the whole body blanket will be taken and the blankets that the clinic routinely use for each patient will be covered to cover the patients' body.
Study: NCT04818632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9833
Description: Part A: AZD9833 monotherapy dose escalation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9833
Description: Part B: AZD9833 monotherapy dose expansion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9833 with palbociclib
Description: Part B: AZD9833 with palbociclib dose expansion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9833 with everolimus
Description: Part B: AZD9833 with everolimus dose expansion
Study: NCT04640571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pravastatin and chenodeoxycholic acid, after metformin and placebo
Description: single oral dose of pravastatin 80 mg and chenodeoxycholic acid 250 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pravastatin and chenodeoxycholic acid, after metformin and placebo
Description: single oral dose of pravastatin 80 mg and chenodeoxycholic acid 250 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pravastatin and chenodeoxycholic acid, after metformin and placebo
Description: single oral dose of pravastatin 80 mg and chenodeoxycholic acid 250 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pravastatin and chenodeoxycholic acid, after metformin and placebo
Description: single oral dose of pravastatin 80 mg and chenodeoxycholic acid 250 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pravastatin and chenodeoxycholic acid, after metformin and placebo
Description: single oral dose of pravastatin 80 mg and chenodeoxycholic acid 250 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pravastatin and chenodeoxycholic acid, after metformin and placebo
Description: single oral dose of pravastatin 80 mg and chenodeoxycholic acid 250 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valacyclovir, chenodeoxycholic acid, and enalaprilat, after polysorbate 80 and placebo
Description: single oral dose of valacyclovir 500 mg, chenodeoxycholic acid 250 mg, and enalaprilat 20 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valacyclovir, chenodeoxycholic acid, and enalaprilat, after polysorbate 80 and placebo
Description: single oral dose of valacyclovir 500 mg, chenodeoxycholic acid 250 mg, and enalaprilat 20 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valacyclovir, chenodeoxycholic acid, and enalaprilat, after polysorbate 80 and placebo
Description: single oral dose of valacyclovir 500 mg, chenodeoxycholic acid 250 mg, and enalaprilat 20 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valacyclovir, chenodeoxycholic acid, and enalaprilat, after polysorbate 80 and placebo
Description: single oral dose of valacyclovir 500 mg, chenodeoxycholic acid 250 mg, and enalaprilat 20 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valacyclovir, chenodeoxycholic acid, and enalaprilat, after polysorbate 80 and placebo
Description: single oral dose of valacyclovir 500 mg, chenodeoxycholic acid 250 mg, and enalaprilat 20 mg
Study: NCT06085365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunonutrition （Su yusu)
Description: Immunonutrition （Su yusu） 250ml oral twice a day d1-d21
Study: NCT05965648

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Families FORWARD (Focusing on Relationships, Well-being, and Responsibility aheaD)
Description: Families FORWARD aims to engage families in planning for adulthood earlier and more actively. Program skills include communication and problem-solving; guided practice in setting realistic goals, breaking down goals into incremental action steps, and problem-solving barriers to goal attainment; repeated engagement in future-oriented communication; and training on how to navigate transition-related and adult services. Parents/caregivers will participate in six or seven telehealth sessions (60-75 minutes each). Youth on the autism spectrum will have the option of participating in up to three program sessions to increase collaborative planning within the family. Families will identify and work toward individualized transition planning goals that may fall within any area of planning or functioning (e.g., housing, education, guardianship).
Study: NCT06165627

Intervention type: DEVICE
Group type: OTHER
Intervention: Lehfilcon A toric contact lenses
Description: Commercially available soft contact lenses worn as indicated

Intervention type: DEVICE
Group type: OTHER
Intervention: Lehfilcon A toric contact lenses
Description: Commercially available soft contact lenses worn as indicated

Intervention type: DEVICE
Group type: OTHER
Intervention: Comfilcon A toric contact lenses
Description: Commercially available soft contact lenses) worn as indicated

Intervention type: DEVICE
Group type: OTHER
Intervention: Comfilcon A toric contact lenses
Description: Commercially available soft contact lenses) worn as indicated

Intervention type: DEVICE
Group type: OTHER
Intervention: CLEAR CARE
Description: Commercially available hydrogen peroxide-based solution for daily cleaning and disinfection of contact lenses used as indicated

Intervention type: DEVICE
Group type: OTHER
Intervention: CLEAR CARE
Description: Commercially available hydrogen peroxide-based solution for daily cleaning and disinfection of contact lenses used as indicated
Study: NCT05284539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed, Cisplatin, Bevacizumab Plus Pembrolizumab
Description: Pemetrexed, 500mg/m2, ivgtt, every 21 days. Bevacizumab 15mg/kg, ivgtt, every 21 days. Pembrolizumab, 200mg ivgtt, every 21 days. Atezolizumab, 1200mg, ivgtt, every 21 days.
Study: NCT04640571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valacyclovir, chenodeoxycholic acid, and enalaprilat, after polysorbate 80 and placebo
Description: single oral dose of valacyclovir 500 mg, chenodeoxycholic acid 250 mg, and enalaprilat 20 mg
Study: NCT05608733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epidural catheter
Description: Bony landmarks and the space between the lower lumbar vertebrae are identified. Subsequently, infiltration of the skin and subcutaneous cellular tissue with local anesthetic (Lidocaine 2% without epinephrine) is performed at the site to be punctured. A 17G Tuohy needle is inserted 2-4 cm through the skin, then the mandrel is removed, the low-resistance syringe is connected, and the loss of resistance is checked using the air or liquid technique, depending on the preference of the anesthesiologist. . Appreciating the loss of resistance in the embolus, the mandrel is then withdrawn and the epidural catheter is advanced to leave it an additional 5 cm inside the epidural space.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continuous sciatic nerve block
Description: The patient is placed in the prone or supine position with the limb to be blocked flexed at 90°. Using a high-frequency linear transducer and using sterile technique, the popliteal sciatic nerve is identified in an axial axis. A 17G Tuohy needle is inserted plane and medial. Saline solution (5 ml) is applied to open the perineural space. Adequate hydrodissection and donut sign in the nerve are observed..A perineural catheter is then advanced 5 cm beyond the tip of the needle. The catheter is fixed with stitches and a transparent sterile dressing is placed.
Study: NCT04864821

Intervention type: DRUG
Group type: OTHER
Intervention: Targeting CD276 CAR T cells
Description: Targeting CD276 autologous chimeric antigen receptor T cells
Study: NCT05753189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aceclidine+Brimonidine combination ophthalmic solution
Description: Combination ophthalmic solution of Aceclidine and Brimonidine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: Proprietary Vehicle Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aceclidine Ophthalmic Solution
Description: Aceclidine
Study: NCT05284539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed, Cisplatin, Bevacizumab Plus Pembrolizumab
Description: Pemetrexed, 500mg/m2, ivgtt, every 21 days. Bevacizumab 15mg/kg, ivgtt, every 21 days. Pembrolizumab, 200mg ivgtt, every 21 days. Atezolizumab, 1200mg, ivgtt, every 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed, Cisplatin, Bevacizumab Plus Pembrolizumab
Description: Pemetrexed, 500mg/m2, ivgtt, every 21 days. Bevacizumab 15mg/kg, ivgtt, every 21 days. Pembrolizumab, 200mg ivgtt, every 21 days. Atezolizumab, 1200mg, ivgtt, every 21 days.
Study: NCT06286371

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Endometriosis Surgery
Description: Laparoscopic Excision of Deep Endometriotic Nodule related to pelvic pain
Study: NCT04554004

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CCTA, CT-MPI, DSA, FFR
Description: The patients who enrolled the study will undergo coronary CT angiography(CCTA), dynamic CT-MPI, invasive coronary angiography and invasive computation of fractional flow reserve (FFR)
Study: NCT05503927

Intervention type: OTHER
Intervention: No Intervention
Description: This is a non-interventional study, therefore no intervention is used.

Intervention type: OTHER
Intervention: No Intervention
Description: This is a non-interventional study, therefore no intervention is used.

Intervention type: OTHER
Intervention: No Intervention
Description: This is a non-interventional study, therefore no intervention is used.
Study: NCT05562271

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-dose radiation therapy
Description: low-dose radiation therapy to involved knee joint

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-dose radiation therapy
Description: low-dose radiation therapy to involved knee joint

Intervention type: RADIATION
Group type: SHAM_COMPARATOR
Intervention: sham radiation therapy
Description: sham radiation therapy to involved knee joint
Study: NCT05977478

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SPECTRA IMDx™
Description: In this study, SPECTRA IMDxTM system will be used to capture the Raman spectra to correlate to histopathology results and mass spectrometry profiling results.
Study: NCT05840029

Intervention type: PROCEDURE
Intervention: VIDEO-ASSISTED THORACOSCOPIC SURGERY
Description: A minimally invasive approach, to not only drain the pleural effusion but also evaluate macroscopic pleural disease and, when possible, resect gross tumor.

Intervention type: PROCEDURE
Intervention: VIDEO-ASSISTED THORACOSCOPIC SURGERY
Description: A minimally invasive approach, to not only drain the pleural effusion but also evaluate macroscopic pleural disease and, when possible, resect gross tumor.
Study: NCT05578001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pilocarpine Ophthalmic
Description: 1 drop of Pilocarpine 1%
Study: NCT05694000

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: On-Stimulation
Description: The surgical electrode implanted in hippocampus by a pulse generating device is on.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Off-Stimulation
Description: The surgical electrode implanted in hippocampus by a pulse generating device is off.
Study: NCT04667143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retagliptin, Henagliflozein, metformin XR
Description: Retagliptin-DPP4 inhibitor Henagliflozein-SGLT-2 inhibitor Metformin XR

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retagliptin, Henagliflozein, metformin XR
Description: Retagliptin-DPP4 inhibitor Henagliflozein-SGLT-2 inhibitor Metformin XR

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retagliptin, Henagliflozein, metformin XR
Description: Retagliptin-DPP4 inhibitor Henagliflozein-SGLT-2 inhibitor Metformin XR

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retagliptin, Henagliflozein, metformin XR
Description: Retagliptin-DPP4 inhibitor Henagliflozein-SGLT-2 inhibitor Metformin XR

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retagliptin, Henagliflozein, metformin XR
Description: Retagliptin-DPP4 inhibitor Henagliflozein-SGLT-2 inhibitor Metformin XR
Study: NCT06085365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil based chemotherapy regimens
Description: fluorouracil based chemotherapy regimens

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: fluorouracil based chemotherapy regimens
Description: fluorouracil based chemotherapy regimens
Study: NCT05555095

Intervention type: BEHAVIORAL
Intervention: digital health delivered multicomponent intervention
Description: The MIC program will have set minimum levels of connectivity for each of the three defined conditions under study.

Intervention type: BEHAVIORAL
Intervention: digital health delivered multicomponent intervention
Description: The MIC program will have set minimum levels of connectivity for each of the three defined conditions under study.

Intervention type: BEHAVIORAL
Intervention: digital health delivered multicomponent intervention
Description: The MIC program will have set minimum levels of connectivity for each of the three defined conditions under study.

Intervention type: BEHAVIORAL
Intervention: digital health delivered multicomponent intervention
Description: The MIC program will have set minimum levels of connectivity for each of the three defined conditions under study.

Intervention type: BEHAVIORAL
Intervention: digital health delivered multicomponent intervention
Description: The MIC program will have set minimum levels of connectivity for each of the three defined conditions under study.
Study: NCT05994599

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: EVE119 vaginal ring
Description: EVE119 (ethinyl estradiol/etonogestrel) vaginal ring delivering 0.015 mg/0.12 mg dose per day

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Nuvaring vaginal ring
Description: Nuvaring® (ethinyl estradiol/etonogestrel) vaginal ring delivering 0.015 mg/0.12 mg dose per day
Study: NCT03706729

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spraino
Description: Spraino® is an adhesive polytetrafluoroethylene (PTFE or Teflon) patch developed with the purpose of minimizing lateral shoe-surface friction whenever initial contact is carried out in an inverted position of the ankle joint. Each Spraino® PTFE patch has a minimum durability of 20 hours use and will be provided by the study sponsor, Spraino® ApS. The participants will receive four pairs of Spraino® upon their enrollment to the study.
Study: NCT05531903

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Description of Slow pathway signals to facilitate ablation
Description: 3D endocardial mapping in order to identify slow pathway signals and abolish or modificate them after radiofrequency ablation
Study: NCT05620017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT8008 for Injection
Description: Intravenous infusion, once every 2 weeks (Q2W). It is recommended that the infusion time of the first cycle should be ≥ 3 hours. If no infusion reaction occurs, the subsequent circulation can be completed within 1-2 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT8008 for Injection
Description: Intravenous infusion, once every 2 weeks (Q2W). It is recommended that the infusion time of the first cycle should be ≥ 3 hours. If no infusion reaction occurs, the subsequent circulation can be completed within 1-2 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT8008 for Injection
Description: Intravenous infusion, once every 2 weeks (Q2W). It is recommended that the infusion time of the first cycle should be ≥ 3 hours. If no infusion reaction occurs, the subsequent circulation can be completed within 1-2 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT8008 for Injection
Description: Intravenous infusion, once every 2 weeks (Q2W). It is recommended that the infusion time of the first cycle should be ≥ 3 hours. If no infusion reaction occurs, the subsequent circulation can be completed within 1-2 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT8008 for Injection
Description: Intravenous infusion, once every 2 weeks (Q2W). It is recommended that the infusion time of the first cycle should be ≥ 3 hours. If no infusion reaction occurs, the subsequent circulation can be completed within 1-2 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT8008 for Injection
Description: Intravenous infusion, once every 2 weeks (Q2W). It is recommended that the infusion time of the first cycle should be ≥ 3 hours. If no infusion reaction occurs, the subsequent circulation can be completed within 1-2 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT8008 for Injection
Description: Intravenous infusion, once every 2 weeks (Q2W). It is recommended that the infusion time of the first cycle should be ≥ 3 hours. If no infusion reaction occurs, the subsequent circulation can be completed within 1-2 hours.
Study: NCT04755140

Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: The patient and an informant will be asked to complete a questionnaire about his or hers current and past physical thinking abilities.

Intervention type: BEHAVIORAL
Intervention: Interviews
Description: Cognition and memory interviews will take place with the patient.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Test
Description: Three blood draws will occur to assess patients immune response, metal levels, and cardiac health.

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiogram
Description: Each echocardiogram takes about 3 hours and 30 minutes. This test uses sound waves to look at your heart. The person doing the test will press on your chest with a machine to obtain the pictures. The pressure may be uncomfortable. The echocardiogram will involve an image enhancement agent infusion to obtain better images.